News
9 Sep 2021
Sterile manufacturing Annex 1 amendments: what, why and how explained
In January 2020 the European Commission published some proposed significant revisions to Annex 1, the EU’s good manufacturing practice (GMP) guide for the manufacture of sterile products. In the following three-month consultation period, affected organisations and stakeholders from over 70 different countries submitted more than 2,000 comments to the proposed update.
In this article Dr. Thomas Becker, Director Quality at Recipharm in Wasserburg, discusses the key changes to the guide and the impact it will have on companies responsible for the manufacture of sterile products as the industry continues to work to meet the industry’s changing requirements and overcome reoccurring challenges in the supply chain.
Mentioned Companies
Recipharm AB
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance